Agenda

Evolving Treatment Paradigms for HR+ Breast Cancer

Seth A. Wander, MD, PHD

‍

Audience Q&A

Seth A. Wander, MD, PHD

‍

Emerging Insights Related to MRD Testing in HR+ Early Breast Cancer

Arielle J. Medford, MD

‍

Audience Q&A

Arielle J. Medford, MD

‍

Adjuvant CDK 4/6 Blockade for Early Stage HR+ Breast Cancer

Claudine Isaacs, MD

‍

Audience Q&A

Claudine Isaacs, MD